Compare Stocks: IBRX, BIIB, ALNY, and BNTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$236.22 +3.0%	$267.02	$197.81 ▼ $495.55	$30.68B	0.3	2.35 million shs	1.90 million shs
BIIB Biogen	$216.78 +1.1%	$205.53	$131.52 ▼ $222.15	$31.67B	0.17	957,736 shs	722,347 shs
BNTX BioNTech	$116.57 +5.1%	$93.43	$79.52 ▼ $124.00	$28.04B	1.27	1.50 million shs	2.96 million shs
IBRX ImmunityBio	$7.79 -0.6%	$7.78	$1.95 ▼ $12.43	$8.31B	0.03	8.87 million shs	7.59 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+3.02%	+3.31%	-11.52%	-20.58%	-48.46%
BIIB Biogen	+1.13%	+3.31%	+9.63%	+11.88%	+55.97%
BNTX BioNTech	+5.12%	+25.22%	+26.94%	+26.51%	+4.73%
IBRX ImmunityBio	-0.64%	+2.91%	+3.73%	+7.89%	+244.69%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$236.22 +3.0%	$267.02	$197.81 ▼ $495.55	$30.68B	0.3	2.35 million shs	1.90 million shs
BIIB Biogen	$216.78 +1.1%	$205.53	$131.52 ▼ $222.15	$31.67B	0.17	957,736 shs	722,347 shs
BNTX BioNTech	$116.57 +5.1%	$93.43	$79.52 ▼ $124.00	$28.04B	1.27	1.50 million shs	2.96 million shs
IBRX ImmunityBio	$7.79 -0.6%	$7.78	$1.95 ▼ $12.43	$8.31B	0.03	8.87 million shs	7.59 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	+3.02%	+3.31%	-11.52%	-20.58%	-48.46%
BIIB Biogen	+1.13%	+3.31%	+9.63%	+11.88%	+55.97%
BNTX BioNTech	+5.12%	+25.22%	+26.94%	+26.51%	+4.73%
IBRX ImmunityBio	-0.64%	+2.91%	+3.73%	+7.89%	+244.69%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.96	Moderate Buy	$386.62	63.67% Upside
BIIB Biogen	2.58	Moderate Buy	$227.07	4.75% Upside
BNTX BioNTech	2.74	Moderate Buy	$127.81	9.64% Upside
IBRX ImmunityBio	2.71	Moderate Buy	$14.20	82.28% Upside

Current Analyst Ratings Breakdown

Latest IBRX, BIIB, ALNY, and BNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$318.00
8/18/2026	ALNY Alnylam Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2026	ALNY Alnylam Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$316.00 ➝ $256.00
8/13/2026	BIIB Biogen	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$300.00
8/12/2026	BIIB Biogen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
8/5/2026	BNTX BioNTech	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$142.00
8/5/2026	BNTX BioNTech	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$130.00 ➝ $125.00
8/4/2026	ALNY Alnylam Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$410.00 ➝ $315.00
8/4/2026	BIIB Biogen	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$221.00 ➝ $241.00
8/3/2026	BIIB Biogen	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$200.00 ➝ $215.00
8/3/2026	ALNY Alnylam Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$380.00 ➝ $340.00

(Data available from 8/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	8.51	$2.88 per share	82.01	$10.12 per share	23.34
BIIB Biogen	$9.89B	3.24	$22.89 per share	9.47	$127.56 per share	1.70
BNTX BioNTech	$3.25B	9.08	$1.40 per share	83.06	$81.64 per share	1.43
IBRX ImmunityBio	$113.29M	72.88	N/A	N/A	($0.99) per share	-7.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	43.91	24.48	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
BIIB Biogen	$1.29B	$5.65	38.37	13.32	6.68	8.32%	11.18%	6.88%	10/29/2026 (Estimated)
BNTX BioNTech	-$1.29B	-$7.83	N/A	N/A	N/A	-63.54%	-6.86%	-6.00%	11/3/2026 (Estimated)
IBRX ImmunityBio	-$351.40M	-$0.97	N/A	N/A	N/A	-598.55%	N/A	-51.65%	11/3/2026 (Estimated)

Latest IBRX, BIIB, ALNY, and BNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2026	Q2 2026	BNTX BioNTech	-$2.3983	-$2.5340	-$0.1357	-$3.70	$180.18 million	$122.31 million
8/4/2026	Q2 2026	IBRX ImmunityBio	-$0.08	-$0.22	-$0.14	-$0.22	$49.70 million	$51.24 million
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	$1.84	+$0.21	$1.21	$1.32 billion	$1.29 billion
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
BIIB Biogen	0.39	1.87	1.26
BNTX BioNTech	0.01	7.85	7.80
IBRX ImmunityBio	N/A	5.72	5.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
BNTX BioNTech	15.52%
IBRX ImmunityBio	8.58%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
BIIB Biogen	0.25%
BNTX BioNTech	19.20%
IBRX ImmunityBio	66.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
IBRX ImmunityBio	590	1.06 billion	359.28 million	Optionable

IBRX, BIIB, ALNY, and BNTX Headlines

Recent News About These Companies

SLS, IBRX stocks in focus: Analyst says Moderna-Merck cancer vaccine success bodes well for oncology

August 21 at 8:23 AM | msn.com

Bell & Brown Wealth Advisors LLC Makes New $657,000 Investment in ImmunityBio, Inc. $IBRX

August 20 at 6:00 AM | defenseworld.netD

ImmunityBio, Inc. (NASDAQ:IBRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 19 at 4:28 AM | marketbeat.com

147,000 Shares in ImmunityBio, Inc. $IBRX Purchased by Hussman Strategic Advisors Inc.

August 15, 2026 | marketbeat.com

SLS and IBRX eye green weekly close: Vanguard’s major stakes in cancer drugmakers steal the spotlight

August 13, 2026 | msn.com

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

August 10, 2026 | aol.comA

Royal Bank of Canada Has $11.40 Million Holdings in ImmunityBio, Inc. $IBRX

August 9, 2026 | marketbeat.com

The Bull Case For ImmunityBio (IBRX) Could Change Following ANKTIVA’s Broad UAE Approval And Ongoing Losses

August 7, 2026 | finance.yahoo.com

Q3 Earnings Estimate for ImmunityBio Issued By HC Wainwright

August 6, 2026 | marketbeat.com

IBRX founder Soon-Shiong bets on Anktiva's next growth phase — ImmunityBio posts record Q2 sales

August 5, 2026 | msn.com

ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

August 5, 2026 | aol.comA

IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake

August 5, 2026 | zacks.com

HC Wainwright Increases Earnings Estimates for ImmunityBio

August 5, 2026 | marketbeat.com

ImmunityBio (NASDAQ:IBRX) Posts Earnings Results, Misses Estimates By $0.14 EPS

August 4, 2026 | marketbeat.com

ImmunityBio (NASDAQ:IBRX) Shares Gap Down on Disappointing Earnings

August 4, 2026 | marketbeat.com

ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates

August 4, 2026 | zacks.com

ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

August 4, 2026 | businesswire.com

Cetera Investment Advisers Has $7.26 Million Stock Holdings in ImmunityBio, Inc. $IBRX

August 2, 2026 | marketbeat.com

Arete Wealth Advisors LLC Makes New Investment in ImmunityBio, Inc. $IBRX

August 1, 2026 | marketbeat.com

ImmunityBio Says Anktiva Receives UAE Marketing Authorization for Certain Bladder, Lung Cancers

July 30, 2026 | finance.yahoo.com

ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug

July 30, 2026 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBRX, BIIB, ALNY, and BNTX Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$236.22 +6.92 (+3.02%)

As of 08/21/2026 04:00 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$216.78 +2.43 (+1.13%)

As of 08/21/2026 04:00 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BioNTech NASDAQ:BNTX

$116.57 +5.68 (+5.12%)

As of 08/21/2026 04:00 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

ImmunityBio NASDAQ:IBRX

$7.79 -0.05 (-0.64%)

As of 08/21/2026 04:00 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBRX, BIIB, ALNY, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBRX, BIIB, ALNY, and BNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBRX, BIIB, ALNY, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBRX, BIIB, ALNY, and BNTX Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

BioNTech NASDAQ:BNTX

ImmunityBio NASDAQ:IBRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IBRX, BIIB, ALNY, and BNTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IBRX, BIIB, ALNY, and BNTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IBRX, BIIB, ALNY, and BNTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBRX, BIIB, ALNY, and BNTX Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

BioNTech NASDAQ:BNTX

ImmunityBio NASDAQ:IBRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools